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esponsibility of InstAbstract The aim of this study was to prepare a dextran–coated layered double hydroxide
acetylsalicylic acid (DEX–LDH–ASA) delivery system by co-precipitation of LDH–ASA and its in-situ
compositing with DEX. The structure of the system was investigated using X-ray diffraction (XRD),
Fourier transform infrared spectroscopy (FT-IR) and thermogravimetry (TG). Its in vitro drug release
properties and in vivo pharmacokinetics in rabbit were also determined. The results show that the DEX–
LDH–ASA system retained the crystal structure of LDH–ASA and gave a marked improvement in its
dispersion. It also prolonged the release of ASA and shifted the release pattern from ﬁrst-order to zero-
order kinetics. The pharmacokinetics of ASA administered in the DEX–LDH–ASA system to rabbits
produced two absorption peaks with a Cmax of 14.871.7 mg/L at 2.1170.69 h and an elimination half-
life of 2.2570.84 h for the ﬁrst peak. The fact that delivery of ASA in the DEX–LDH–ASA system was
sustained with improved bioavailability indicates the potential of the system as a controlled release
formulation with application to other drugs.
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Characterization of a DEX–LDH–ASA and its pharmacokinetics in rabbit 4011. Introduction
Traditionally acetylsalicylic acid (ASA) has been used as an
antipyretic, analgesic and antiinﬂammatory drug marketed under
the trade name aspirin. Extensive clinical research has shown that
ASA is useful in the prevention of cerebral thrombosis, coronary
heart disease, myocardial infarction, ischemic stroke, transient
ischemic attack, unstable angina and postoperative thrombosis.
However, oral administration of ASA is associated with severe
irritation to the gastrointestinal tract mucosa leading to a number
of adverse effects including nausea, vomiting, ulceration and
bleeding. To reduce these adverse effects and maintain or even
improve its beneﬁcial effects has led to the development of some
oral controlled release systems1–4.
Layered double hydroxide (LDH), also known as hydrotalcite-
like material or anionic clay, is a supramolecular material
consisting of layers of electropositive hydroxides of divalent (MII)
and trivalent (MIII) metals and interlayer anions (Am)5. LDH is
currently described by the general formula [MII1xM
III
x (OH)2]
xþ
(Am)x/m  nH2O, where x represents the ratio of [M3þ]/([M2þ]þ
[M3þ]). Due to the anion exchange properties of LDH, many
pharmaceutically active compounds have been intercalated into the
interlayer of LDH including anticancer, antiinﬂammatory, antihy-
pertensive and cardiovascular drugs 6–15. Owing to electrostatic
interactions and solid geometry, intercalated drugs are stabilized and
usually released in a sustained manner6–12. Early research demon-
strated that intercalation of antiinﬂammatory drugs in the LDH–drug
delivery system changed their release proﬁle7,8, improved their
solubility and reduced their adverse effects9. However, due to the
alkalinity of the LDH laminate, the use of orally administered LDH–
drug delivery systems still remains somewhat problematic8.
Dextran (DEX), an α-D-pyran polysaccharide, is a relatively
non-toxic, biodegradable and water-soluble macromolecule16
commonly used as an auxiliary material for colonic targeting of
drugs17. Its large network of hydroxyl and 1,6-α-glycosidic bonds
makes it suitable to provide a protective layer over the LDH–drug
system to eliminate the acid corrosion for the LDH laminate18–20.
Taking advantage of this, we assembled a supramolecular ASA
delivery system composed of LDH loaded ASA with a DEX
coating on the surface. The present study was undertaken to
elucidate the structure of this DEX–LDH–ASA system and
evaluate its in vitro ASA release proﬁle and ASA pharmacoki-
netics after oral administration in rabbit.2. Materials and methods
2.1. Materials
ASA (BR) was purchased from the Fourth Pharmaceutical Co.
Ltd. (Zhonglian Group, Wuhan, China). Magnesium chloride
(MgCl2  6H2O), aluminum chloride (AlCl3  6H2O) and potassium
dihydrogen phosphate (KH2PO4 H2O) were analytical grade from
Laiyang Chemical Co., Ltd. (Shandong, China). Salicylic acid
(SA) was analytical grade from the China Institute of Food and
Drug Control. Benzoic acid and ethyl acetate were purchased from
the North Sky Medicinal Chemistry Reagent Factory (Tianjin,
China). HPLC grade methanol was purchased from Jiangtian
Chemical Technology Co., Ltd. (Tianjin, China). Deionized water
was used in all experiments. Healthy rabbits (n¼12, weight
2.570.3 kg) were supplied by the Animal Center of Ningxia
Medical University.2.2. Instrumentation
Powder X-ray diffraction (XRD) patterns were recorded in the range
5–801 on a Rigaku D/Max-rB diffractometer using Cu Kα radiation
(λ¼0.1542 nm) at 30 kV and 30 mA and a dwell time of 21 per
minute. Fourier transform infrared spectra (FT-IR) were recorded in
the range 400–4000 cm1 on a TENEOR27 IR spectrophotometer
(Brooke Company, Germany) with 4 cm1 resolution using the
KBr disc method. Particle size was determined using a United States
PSS NICOMPTM 380 submicron particle size analyzer. Analysis of
ASA to determine its loading and release rate was carried out using
a Unico UV-3802 UV/VIS spectrophotometer (Unico Instrument
Co. Ltd., Shanghai, China). Blood concentrations of SA were
determined by HPLC on a HITACHI 2000 HPLC system equipped
with an Allsphere ODS column (250 mm 4.6 mm, 5 μm) main-
tained at 25 1C using a mobile phase of methanol:pH 6.8 KH2PO4
buffer (1:3, v/v) at a ﬂow rate of 1 mL/min. Detection was by UV
absorption at 240 nm.
2.3. Synthesis of the DEX–LDH–ASA system
The intercalated LDH–ASA complex was prepared using the co-
precipitation method8,13,18. An aqueous 2.0 M NaOH solution was
added dropwise to 850 mL of an aqueous, magnetically stirred
(300 rpm) solution containing MgCl2  6H2O (40.82 g), AlCl3
 6H2O (24.30 g) and ASA (72.83 g) maintained at 80 1C under
a nitrogen atmosphere. When the pH reached 10.6, the slurry was
maintained at 80 1C for a further 30 min to produce the aged
slurry. To obtain the solid LDH–ASA complex, the slurry was
centrifuged and the solid material collected, washed sequentially
with water, ethanol and diethyl ether and ﬁnally dried in an oven at
65 1C. The solid product was denoted L2 (LDH–ASA secondary
compound).
An aqueous solution containing 32.20 g dextran in 200 mL
deionized water was added to the aged magnetically stirred LDH–
ASA slurry prepared as described above. The hot slurry was then
poured into 100 mL cold ethanol which was previously maintained
at 80 1C for 24 h to segregate solid with the method of in situ
solvent conversion18,19. The ethanol suspension was maintained
under a nitrogen atmosphere for 3 h at room temperature before
being centrifuged, washed with water and ﬁnally dried in an oven
at 60 1C. The product was denoted L3 (DEX–LDH–ASA triple
composite).
2.4. In vitro release of ASA from the LDH–ASA system
2.4.1. Drug loading
The L2 and L3 samples were powdered in a pestle and mortar and
sifted through a 100-mesh screen. Samples (0.2000 g) of powders
were then dissolved in the minimum amount of concentrated HCl,
transferred to 50 mL volumetric ﬂasks and made up to volume. An
aliquot (5 mL) was removed, ﬁltered through a 0.22 μm ﬁlter
membrane and 2.00 mL of the ﬁltrate diluted to 10.00 mL. The
ASA concentration in this solution was then determined from its
absorption at 303 nm. All experiments were carried out in
triplicate. The results showed that the drug loadings of ASA in
L2 and L3 were 28.2% and 13.5%, respectively.
2.4.2. Drug release of ASA
Drug release proﬁles were determined in phosphate buffered saline
(PBS, pH 7.50) at 3770.5 1C using a closed circulation system.
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distilled water until the absorbance of the ultraviolet detector
remained at zero. After draining the system by operating the pump
in the opposite direction for 15 min, 500 mL PBS solution was
introduced through a 0.22 μm ﬁlter and circulated in the forward
direction while the detector was adjusted to zero. A sample
(0.2500 mg) of L2 or L3 was then added to the dissolution cup
and the absorbance and pH monitored for 60 min using a rotation
speed of 100 rpm.
2.5. Pharmacokinetic study in rabbit
2.5.1. Animal protocol
The single-dose, open-label, randomized, two-period crossover
study was approved by the Ethics Committee for Animal
Experimentation of Ningxia Medical University. Animals were
fasted with ad libitum access to water for 12 h before dosing to 4 h
after dosing. Rabbits were administered by gavage an aqueous
suspension of 50 mg ASA by gavage as either DEX–LDH–ASA
or pure ASA with a 1-week washout period. Blood samples
(2.5 mL) were collected from the auricular vein into heparinized
tubes before drug administration and after pure aspirin at 0.25,
0.40, 0.60, 0.80, 1.0, 1.25, 1.40, 1.70, 2.0, 2.25, 2.50, 3.0 and
4.0 h and after DEX–LDH–ASA at 0.11, 0.19, 0.5, 1, 2, 4, 6, 8,
10, 12, 14, 16, 18, 23.5, 28, 33, 37, 41, 55 and 60.5 h. Blood
samples were centrifuged immediately at 3000 rpm for 15 min and
plasma stored at 20 1C in coded glass tubes pending analysis.
2.5.2. HPLC assay
Plasma concentrations of SA were determined by HPLC using
benzoic acid as internal standard (IS) because ASA was ultimately
translated into SA in vivo. Stock solutions of SA and benzoic acid
(1 mg/mL) were prepared in methanol and diluted to obtain an
0.1 mg/mL SA standard solution and an 0.1 mg/mL working IS
solution respectively. Aliquots (500 μL) of blank rabbit plasma
were then spiked with SA standard solution to give calibration
standards with concentrations of 0.1, 0.5, 1, 2, 4, 10, 16, 24 and
32 mg/mL1,4. Quality control (QC) samples (1, 10 and 60 mg/mL)
were prepared in the same way.
Plasma samples were thawed at room temperature and 500 μL
aliquots pipetted into Eppendorf tubes. After adding 20 μL
aliquots of IS working solution, the mixture was vortex mixed
and 200 μL aliquots of monopotassium phosphate buffer (0.5 M
ﬁltered through 0.45 μm ﬁlters) added. After shaking for 1–2 min,
3 mL ethyl acetate was added and the samples vortexed for 10 min
and centrifuged for 15 min at 3000 rpm. Upper organic layers were
transferred to clean tubes and the aqueous phase extracted again
with 2 mL ethyl acetate. The two extracts were mixed and
evaporated to dryness in a vacuum drying oven at 0.8 mPa and
55 1C. Residues were reconstituted in 300 μL monopotassiumTable 1 Results of the determination of recovery and precision for
Spiked concentration (mg/mL) Concentration found (mg/mL)
1.0 0.85270.025
10 9.7670.28
16 16.5470.50phosphate solution (0.025 M), vortexed for 10 min and centrifuged
at 3000 rpm for 15 min. Finally samples were ﬁltered through
0.22 μm ﬁlters and 20 μL aliquots injected into the HPLC system.
Concentration of SA was determined from peak areas of analyte
and IS.
The assay was linear (C¼1.2704þ3.1662 R, r2¼0.9942) with
a limit of quantitation of 0.1 mg/L. Results of assay validation for
recovery and precision based on QC samples are shown in
Table 1. The results show the method was satisfactory for the
determination of SA in biological samples1–4.
2.5.3. Pharmacokinetic analysis
Pharmacokinetic parameters were determined from plasma con-
centration–time curves using the DAS 2.0 method. The maximum
observed concentration (Cmax) and time to Cmax (Tmax) were read
directly from the data. Areas under plasma concentration–time
curves (AUCs) were calculated using the linear trapezoidal rule
from time zero to t (AUC0–t).3. Results and discussion
3.1. Characterization of the ASA-loaded LDH delivery system
The X-ray diffraction patterns of L2 and L3 are depicted in Fig. 1.
Fig. 1A represents the XRD of Mg6Al2(OH)12  4.5H2O recorded
by the standard card 35-0965 of the Joint Committee on Powder
Diffraction Standards which represents the standard model of the
R-3m [166] crystal system. Fig. 1B shows the 003, 006, 0012,
0015, 0018, 110 and 113 reﬂections of sample L2 were found for
2θ at 11.2201, 22.5011, 34.4761, 38.6481, 45.5881, 60.5601 and
61.7941, respectively. The basal spacing scope and the intensity
distribution characteristics of L2 were generally consistent with
those of the 35-0965 model suggesting that the crystal form of
LDH is maintained in the LDH–ASA intercalated system. The
basal spacing of d110 (0.1528 nm) and d113 (0.1500 nm) were
close to those of the 35-0965 standard but the d003, d006, d012, d015
and d018 values of L2 were greater than those of the standard
indicating that the OH and Cl ions in the interlayer of LDH
have been replaced by ASA13. The reﬂection line of the d110
diffraction peak in the LDH–ASA system was unchanged in the
intercalation process indicating that the intercalation of ASA did
not change the structure of the laminate6,9,12. Fig. 1C shows
the diffraction parameters of 003, 006, 0012, 0015, 0018, 110
and 113 in the L3 sample were (11.2791, 0.7839 nm), (22.4391,
0.3959 nm), (34.2591, 0.2615 nm), (38.1251, 0.2359 nm),
(44.7991, 0.2021 nm), (60.5971, 0.1527 nm) and (61.9611,
0.1496 nm), respectively. The diffraction variations in L3 were
similar to those in L2 compared with the 35-0965 standard as
conﬁrmed by the shifting of the 006, 0012, and 0015 diffraction
peaks to low 2θ angles at 22.4391, 34.2591 and 38.1251,the HPLC assay of salicylic acid in rabbit plasma (n¼5).
Recovery (%) Precision (RSD %)
Intra-day Inter-day
85.272.5 3.5670.11 8.9170.21
97.672.8 2.7070.08 6.6570.13
103.473.1 2.8470.08 4.0670.04
Figure 1 XRD patterns of (B) L2 and (C) L3.
Figure 2 IR spectra of (A) DEX, (B) L2 and (C) L3.
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standard. A new peak was found at 6.2781 (Fig. 1C, d¼1.4068
nm) and assigned to the diffraction location of the amorphous
organic polymer. This indicates that the organic phase of DEX was
actually deposited on the surface of L2 rather than intercalated into
its interlayer spaces. Overall, the results of XRD analysis show
that combination with DEX did not change the crystal structure of
the LDH–ASA intercalation system. However, modifying the
LDH–drug delivery system with organic composites will weaken
the ionization of the LDH crystal plane, reduce the toxicity of theloaded drug to biological tissue and improve the cell targeting
efﬁciency of the LDH delivery system17.
The FT-IR spectra of DEX, L2 and L3 are compared in Fig. 2.
DEX showed an intense broad band at 3429.28 cm1 which can
be assigned to the O–H stretch and the sharp absorption peak
(marked with a in Fig. 2A) at 2922.91 cm1 can be assigned to a
C–H vibration. The band at 1159.84 cm1 (marked with b) is due
to νC–OH in DEX and the band at 1012.95 cm1 is due to νC–OH in
–CH2–OH. The FTIR spectra of L2 showed many intense, sharp
absorption peaks, reﬂecting the different functional groups present
L. Dong et al.404in the supramolecular composite. The broad absorption peak at
3475.63 cm1 mainly arises from the O–H stretch in LDH present
within the hydrate layer6,9,12,13. The absorption peak 2 at
1388.52 cm1 is due to the out-of-plane rocking vibration of an
H atom outside the LDH laminate13, while peaks 3 at 664.9 cm1
and 4 at 445.9 cm1 are assigned to metal–oxygen stretches
within the LDH layer6,9,12. These typical bands (marked by 1–4)
correspond to νO–H, δMO–H and νM–O–M stretches indicating that
the structure of LDH is maintained during the intercalation
process12,13,18. The spectrum of L2 in Fig. 2B also shows the
speciﬁc bands of ASA (marked with d, e and f) demonstrating that
ASA anions are intercalated into the interlayer galleries of LDH. In
detail, the intense, broad absorption band at 1620.0–1560.45 cm1
is attributed to the ring vibration mode νAr while the peaks at
1465.19 and 1254.41 cm1 are assigned to the δC–H deformation
mode and νC–O stretch respectively of ester bonds in ASA. The
FTIR spectrum of L3 shown in Fig. 2C clearly includes the main
absorption peaks of DEX, ASA and LDH. The absorption bands
assigned to L2 are found at 3474.60, 1386.49, 666.84 and
447.12 cm1 and attributed to the νO–H, δMO–H and νM–O stretches
of LDH, respectively. The increased absorption area and wave-
length range at 3474.60 cm1 for L3 presumably occurs due to a
three-way merger of the νO–H mode present in LDH, DEX and
ASA18. In addition, the absorption peaks of intercalated ASA
corresponding to νAr, δC–H and ν
C–O of ASA (d, e, and f,
respectively) of L2 are found in Fig. 2C at 1575.08, 1460.35,
and 1258.81 cm1 respectively. The characteristic vibrations of
DEX, including νC–H and νC–OH (corresponding to a, b and c)
appear at similar locations in Fig. 2C. The spectrum of L3 shows
the speciﬁc bands of intercalated ASA, supporting LDH and
surface composite DEX but does not appear as a simple super-
position of these components indicating L3 is a supramolecular
assembly rather than a simple mixture of DEX, LDH and ASA.
The thermal behavior of L2 and L3 nanoparticles was examined
using thermogravimetric (TG) and differential thermogravimetric
(DTG) analyses. The results are shown in Fig. 3. Two main
thermal events are clearly observed in L2 (Fig. 3A). The ﬁrst
occurs in the region 68.5–158.2 1C and is attributed to the removal
of adsorbed water on the external surface of LDH and water within
the interlayer of L2
12,13. This corresponds to a sharp peak in the
differential thermogravimetric curve at 115.6 1C with 5.551%Figure 3 Thermal analysisweight loss and an enthalpy 46.58 J/g. The second event occurs
in the region 272.8–434.9 1C and can be attributed to dehydrox-
ylation of the metal hydroxide layers and decomposition and
subtle combustion of intercalated ASA. This corresponds to the
strong endothermic peak at 345.9 1C with 18.61% weight loss and
an enthalpy of 801.1 J/g. The ﬁnal stage of weight loss is related to
the formation of spinel LDO9,16. Fig. 3B shows that L3 exhibits
more complicated thermal behavior than L2 and takes place in
three major stages of weight loss. These occurred at temperature
maxima of 112 1C, 290.3 1C and 425.2 1C with weight losses of
6.476%, 20.02% and 12.32%, respectively, The ﬁrst stage of
weight loss in the range 66.1–168.7 1C can be attributed to the
removal of adsorbed and structured water; it displays a tempera-
ture interval similar to that seen in L2 but with an enthalpy value
up to 2.75 times higher. This suggests that the elimination of
adsorbed water is more difﬁcult in the three-level composite and
that the removal of interlaminar water from LDH is also more
limited. Compared with L2, the mass loss increased by 0.925% in
the same temperature range which can be attributed to the partial
evaporation of DEX. The second stage of weight loss occurred in
the region 209.6–311.4 1C corresponding to a small endothermic
section in the DSC curve at 243.3 1C with 9.735% weight loss and
an enthalpy of 53.3 J/g. This was followed by another event in the
range 331.4–420.1 1C corresponding to a strong broad peak at
373.2 1C with 10.28% weight loss and an enthalpy of 271.4 J/g.
The total weight loss of the two successive events (20.02%) was
greater than that of L2 (18.61%) in the region 272.8–434.9 1C but
the total enthalpy value (324.7 J/g) was about 40% of L2. The
variation in slopes of the DSC and DTG curves shows that the
dehydroxylation of the metal hydroxide layers and the decom-
position of the intercalated ASA is divided into at least two
sections which usually overlap during the second stages of weight
loss in the LDH–ASA system9,16. It has been suggested that the
intercalated material may be involved in the dehydroxylation
process of LDH to form spinel LDO via grafting with LDH and
replacing hydroxyl groups to promote dehydration, condensation
and phase transformation of the hydroxide laminate5,13. In the
three-level composite, the endothermic enthalpy of decomposition
of the LDH laminate decreases and the event is clearly separated
from the subsequent thermal decomposition. This demonstrates
that ASA intercalated between interlayers of the LDH and thecurves of (A) L2 and (B) L3.
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droxylation process leading to the dramatic decline in activation
energy. The disintegration of the residual solid was also facilitated
by the organic functional groups inside and outside the LDH
laminate.
The results of particle size determination showed that for L2 the
mean particle diameter was 184.2 nm with a distribution range
of 20–354 nm and for L3 was 54.9 nm with a distribution of
15–68.3 nm. The smaller size and narrower distribution range of
L3 indicates that the dispersion of the ASA-loaded particle is
improved by DEX. This is most likely due to the inhibition by
DEX of aggregation of the nanoparticles during the drying
process18.Figure 5 Fitting of ASA release from the LDH dosing systems.3.2. In vitro release of ASA from the LDH–ASA system
The cumulative release proﬁles of L2 and L3 in PBS (pH 7.50) are
compared in Fig. 4. Release of ASA from L2 was very rapid with a
clear burst effect occurring over 0–4 min and releasing 73.3% of
the drug. This is probably due to the reduced barrier to release of
drug adsorbed outside the LDH laminate in powder state. This
quick release was followed by a slower release over 56 min which
occurs by exchange of ASA ions and phosphate ions in the buffer
as previously reported8,12,14,15. The reduced barrier to drug release
also results in a slight burst effect for L3 but, in this case, only 30%
ASA was released over 0–4 min indicating that the majority of
drug is encapsulated inside the DEX–LDH–ASA nanocomposite.
The release proﬁle of L3 shows that 45% of the drug was released
after 10 min and 100% after 60 min indicating a more controlled
release of ASA than from L2 and that release of ASA from the
DEX–LDH–ASA system is signiﬁcantly reduced by the DEX
coating18,19.
To gain more insight into the mechanism of release of ASA from
L2 and L3, the data were ﬁtted to zero-order and ﬁrst-kinetic equations.
The results shown in Fig. 5 suggest that release is best described by a
ﬁrst-order equation for L2 (r¼0.9876) and a zero-order equation for
L3 (r¼0.9865). Thus introducing the DEX coating prolongs the
release of ASA and shifts the release pattern from ﬁrst-order to zero-
order. The improved controlled release from the DEX–LDH–ASA
system in vitro led us to test its pharmacokinetics in rabbit.Figure 4 ASA release curves of the LDH dosing systems.3.3. Pharmacokinetics of the DEX–LDH–ASA delivery system in
rabbit
The pharmacokinetics of SA produced by ASA hydrolysis after
release from the DEX–LDH–ASA system was compared with that
produced by ASA itself. Plasma concentration–time proﬁles and
corresponding pharmacokinetic parameters are presented in
Table 2 and Fig. 6. Mean plasma concentrations of ASA over
60 h show that, for ASA administration, the drug concentration
rapidly reached a Cmax of 19.63 mg/L at 1.4 h and then rapidly
decreased to a trough level (0.152 mg/L) after 4 h. In contrast,
after DEX–LDH–ASA administration, two absorption peaks were
clearly observed. The ﬁrst peak reached a Cmax of 14.77 mg/L at
2 h after which the concentration dropped slowly to 0.423 mg/L
over 10 h and then increased again to 3.455 mg/L at 16 h, ﬁnally
falling to 0.199 mg/L at 60 h. The results show clearly that the
DEX–LDH–ASA system provides slow release of drug in vivo.
Moreover, it appears that oral administration of the DEX–LDH–
ASA system produces a higher therapeutic trough plasma con-
centration, prolongs metabolic process and improves the efﬁcacy
of ASA.
There were also clear differences between the other pharmaco-
kinetic parameters. The in vivo absorption half-life, clearance rate
and AUC0 t after administration of ASA were 0.442 h, 2.269 L/h
and 21.15 mg h/L respectively, whereas after administration of the
DEX–LDH–ASA system, the half-life of ASA increased by 5.08-
fold, the clearance rate reduced by 51% and the oral bioavailability
increased by 2.08-fold. In addition, Tmax was delayed and Cmax
was reduced by 25%. These results show that the DEX–LDH–
ASA system improves the bioavailability and decreases the
elimination rate of ASA with the potential to increase its efﬁcacy
and reduce its adverse effects.
The double peak phenomenon in the pharmacokinetics of ASA
administered in the DEX–LDH–ASA system is explicable in terms
of its three-level supramolecular characteristics19. The DEX coat-
ing forms a protective network containing a large number of
hydroxyl groups which not only provide an excellent antacid
effect16–18, but is also stable enough to proceed down the
gastrointestinal tract14. In the gastrointestinal environment, rapid
release of ASA on the surface together with some in the interlayer
results in the ﬁrst drug peak. The remaining DEX–LDH–ASA and
LDH–ASA particles may be involved in enterohepatic recycling
Figure 6 Plasma concentration–time curves of ASA and DEX–
LDH-ASA.
Table 2 Principal pharmacokinetics parameters of ASA after administration of DEX–LDH–ASA and ASA to
rabbits.
Parameter ASA DEX–LDH–ASA
t1/2α (h) 0.44270.202 2.24870.844
AUC0 t (mg  h/L) 21.1573.48 43.9075.85
CL (L/h) 2.26970.554 1.10870.231
Cmax (mg/L) 19.6372.60 14.7771.67
Tmax (h) 1.40170.520 2.11070.693
Data are expressed as mean7SD, n¼6.
L. Dong et al.406and return ASA to the blood after transport via the hepatic portal
vein leading to the second absorption peak. However, it may also
originate from the delayed release of ASA from DEX–LDH–ASA
and LDH–ASA nanoparticles in the blood. This would be
desirable for a controlled release formulation of ASA to realize
its therapeutic effects.4. Conclusions
This work shows that a three-level supramolecular delivery system
(DEX–LDH–ASA) for ASA can be successfully produced by
coating an LDH–ASA complex with DEX. The crystal structure of
the LDH–ASA intercalation system was largely maintained in the
DEX–LDH–ASA supramolecule as demonstrated by X-ray dif-
fraction, FT-IR spectroscopy and thermal behavior. Our results
indicate that the dispersion of ASA-loaded particles and the
in vitro and in vivo release of ASA from the LDH–ASA
intercalation system were signiﬁcantly improved. The results also
show that the three-stage supramolecular assembly provides
superior bioavailability of ASA and reduces its elimination rate.
Overall it is clear that the DEX–LDH–ASA system has potential
as an orally available controlled release drug delivery system
capable of reducing the adverse effects and increasing the
therapeutic efﬁcacy of intercalated drugs.Acknowledgment
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